Autoimmune Disease

RegulatoryJuly 15, 2026

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy

The FDA has granted Priority Review for Gazyva/Gazyvaro based on phase III MAJESTY results showing significant remission rates in primary membranous nephropathy.

Companies

Assets

Recent signals(8)

Pfizer Reports Positive Phase 3 Results for LITFULO in Nonsegmental Vitiligo

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy

FDA Grants Priority Review for Roche's Enspryng in Thyroid Eye Disease

Baricitinib Trial for Job Syndrome Patients with Lupus-Like Disease or Atopic Dermatitis

Regeneron and Sanofi Study Dupilumab for Bullous Pemphigoid in Adults

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study

Upcoming catalysts

Indications

Get signals before the market moves